Jim Simons Greenwich Life Sciences, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 36,900 shares of GLSI stock, worth $495,936. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,900

Previous 37,500 1.6%

Holding current value

$495,936

Previous $748,000 14.97%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$12.07 - $19.04 $7,242 - $11,424	-600 Reduced 1.6%	36,900 $636,000
Q1 2024 May 13, 2024	BUY	$8.31 - $20.32 $7,479 - $18,288	900 Added 2.46%	37,500 $748,000
Q4 2023 Feb 13, 2024	SELL	$7.77 - $12.3 $137,513 - $217,685	-17,698 Reduced 32.59%	36,600 $385,000
Q3 2023 Nov 14, 2023	SELL	$8.41 - $10.66 $209,425 - $265,455	-24,902 Reduced 31.44%	54,298 $480,000
Q2 2023 Aug 11, 2023	BUY	$9.58 - $13.2 $272,072 - $374,880	28,400 Added 55.91%	79,200 $764,000
Q1 2023 May 12, 2023	BUY	$12.12 - $20.8 $212,100 - $364,000	17,500 Added 52.55%	50,800 $701,000
Q4 2022 Feb 13, 2023	SELL	$9.04 - $16.88 $211,545 - $395,008	-23,401 Reduced 41.27%	33,300 $506,000
Q3 2022 Nov 14, 2022	SELL	$7.81 - $12.02 $378,456 - $582,465	-48,458 Reduced 46.08%	56,701 $516,000
Q2 2022 Aug 12, 2022	BUY	$7.14 - $20.36 $750,835 - $2.14 Million	105,159 New	105,159 $891,000
Q1 2022 May 13, 2022	SELL	$16.3 - $24.65 $489,000 - $739,500	-30,000 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$21.76 - $39.43 $652,800 - $1.18 Million	30,000 New	30,000 $730,000

Others Institutions Holding GLSI

# of Institutions

Shares Held

1.01M

Call Options Held

Put Options Held

View Full List

About Greenwich LifeSciences, Inc.

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $173M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

More about GLSI

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account